Advocacy group alleges Sanofi-Shire conspiracy

Share this article:

Shire's March 2012 decision to walk away from the chance to market its drug Replagal in the US and put it in direct competition with Sanofi's Fabrazyme is now being pilloried as a possible conspiracy between the two drugmakers, as opposed to Shire's disinterest in investing in more research for an FDA approval. Both drugs treat the rare condition Fabry disease, in which a specific type of fat accumulates in the cells and can cause kidney and heart disease, among other problems.

The Wall Street Journal reports that a consumer advocacy group alleges that Shire decided to give Sanofi the US market if it would be allowed to sell its drug in Europe, and is asking the Federal Trade Commission to give the situation a once-over.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.